Craniopharyngioma medical therapy: Difference between revisions
Jump to navigation
Jump to search
Marjan Khan (talk | contribs) No edit summary |
Marjan Khan (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The predominant therapy for craniopharyngioma is surgical resection. Adjunctive [[chemotherapy]] and [[radiation]] may be required. Subcutaneous pegylated [[interferon]] alpha-2B has been used to treat cystic recurrences. It can also be treated with intracavitary instillation of radioactive P-32, [[bleomycin]] or [[interferon-alpha]] via [[stereotactic]] delivery or placement of an Ommaya catheter. [[Paclitaxel]] and [[carboplatin]] have shown to prevent recurrence of malignant craniopharyngiomas.Intracavitary bleomycin reduces cyst size and toughens and thickens the cyst wall, thereby facilitating surgical excision of a cyst membrane that otherwise might fragment at the time of open craniotomy. Reports of intracystic bleomycin use are limited. Other agents like interferon alpha are being tested in recent days. | The predominant therapy for craniopharyngioma is [[Resection|surgical resection]]. Adjunctive [[chemotherapy]] and [[radiation]] may be required. Subcutaneous [[Pegylated interferon-alpha-2a|pegylated]] [[interferon]] [[Alpha-2B adrenergic receptor|alpha-2B]] has been used to treat [[Cyst|cystic]] recurrences. It can also be treated with intracavitary instillation of [[Radioactive isotopes|radioactive P-32,]] [[bleomycin]] or [[interferon-alpha]] via [[stereotactic]] delivery or placement of an [[Ommaya reservoir|Ommaya catheter]]. [[Paclitaxel]] and [[carboplatin]] have shown to prevent recurrence of malignant craniopharyngiomas. [[Bleomycin|Intracavitary bleomycin]] reduces cyst size and toughens and thickens the cyst wall, thereby facilitating surgical excision of a cyst membrane that otherwise might fragment at the time of open [[craniotomy]]. Reports of intracystic bleomycin use are limited. Other agents like [[Interferon type I|interferon alpha]] are being tested in recent days. | ||
==Medical Therapy== | ==Medical Therapy == | ||
* | *The mainstay of therapy for craniopharyngioma is surgery with or without [[Radiation therapy|radiation]]. | ||
* | *There are certain [[Indications and usage|indications]] for medical therapy mostly in treating recurrent tumors. | ||
*The chemotherapy drugs [[Paclitaxel]] and [[Carboplatin]] have shown a clinical significance in increasing the survival rate | *The use of subcutaneous [[Interferon-alpha|pegylated interferon alpha-2b]] to manage [[Cyst|cystic]] recurrences can result in durable responses.<ref>Rx of Craniopharyngioma. Cancer gov. http://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq#link/_40_toc</ref> | ||
* | *The [[Chemotherapy|chemotherapy drugs]] [[Paclitaxel]] and [[Carboplatin]] have shown a clinical significance in increasing the survival rate. | ||
*Cystic recurrences may be treated with intracavitary instillation of varying agents via [[stereotactic]] delivery or placement of an Ommaya catheter. | |||
*Stereotactic agents have included radioactive P-32 or other radioactive compounds, [[bleomycin]] or [[interferon-alpha]]. | |||
*None of these approaches have shown efficacy against solid portions of the tumor.<ref>Rx of Craniopharyngioma. Cancer gov. http://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq#link/_40_toc</ref> <ref>Rx of Craniopharyngioma. Cancer gov. http://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq#link/_40_toc</ref> | |||
==References== | ==References== | ||
Revision as of 14:13, 13 February 2019
|
Craniopharyngioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Craniopharyngioma medical therapy On the Web |
|
American Roentgen Ray Society Images of Craniopharyngioma medical therapy |
|
Risk calculators and risk factors for Craniopharyngioma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]
Overview
The predominant therapy for craniopharyngioma is surgical resection. Adjunctive chemotherapy and radiation may be required. Subcutaneous pegylated interferon alpha-2B has been used to treat cystic recurrences. It can also be treated with intracavitary instillation of radioactive P-32, bleomycin or interferon-alpha via stereotactic delivery or placement of an Ommaya catheter. Paclitaxel and carboplatin have shown to prevent recurrence of malignant craniopharyngiomas. Intracavitary bleomycin reduces cyst size and toughens and thickens the cyst wall, thereby facilitating surgical excision of a cyst membrane that otherwise might fragment at the time of open craniotomy. Reports of intracystic bleomycin use are limited. Other agents like interferon alpha are being tested in recent days.
Medical Therapy
- The mainstay of therapy for craniopharyngioma is surgery with or without radiation.
- There are certain indications for medical therapy mostly in treating recurrent tumors.
- The use of subcutaneous pegylated interferon alpha-2b to manage cystic recurrences can result in durable responses.[1]
- The chemotherapy drugs Paclitaxel and Carboplatin have shown a clinical significance in increasing the survival rate.
- Cystic recurrences may be treated with intracavitary instillation of varying agents via stereotactic delivery or placement of an Ommaya catheter.
- Stereotactic agents have included radioactive P-32 or other radioactive compounds, bleomycin or interferon-alpha.
- None of these approaches have shown efficacy against solid portions of the tumor.[2] [3]
References
- ↑ Rx of Craniopharyngioma. Cancer gov. http://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq#link/_40_toc
- ↑ Rx of Craniopharyngioma. Cancer gov. http://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq#link/_40_toc
- ↑ Rx of Craniopharyngioma. Cancer gov. http://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq#link/_40_toc